CD133 as a Marker for Regulation and Potential for Targeted Therapies in Glioblastoma Multiforme

Choy, Winward; Nagasawa, Daniel T.; Trang, Andy; Thill, Kimberly; Spasić, Marko; Yang, Isaac

doi:10.1016/j.nec.2012.04.011

Cited by 31 publications

(33 citation statements)

References 125 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In order to study the properties of GSLCs, we firstly enriched them from two GBM cell lines using serum-free medium supplemented with growth factors as the literature reported [29][30][31]. CD133 is still the most commonly used cell markers of glioma stem cells [6,32] despite some disputes [33]. In our study, we also used nestin and sox-2, another two commonly used stem cell markers [34], to identify whether the enriched cells possessed properties of glioma stem cells.…”

Section: Discussionmentioning

confidence: 99%

Synergistic effect of TRAIL and irradiation in elimination of glioblastoma stem-like cells

et al. 2018

View full text Add to dashboard Cite

Glioblastoma multiforme (GBM) is the most common malignancy in central nervous system. A small subpopulation of GBM cells known as GBM stem-like cells (GSLCs) were supposed to be the most malignant cells among GBM cells as they are resistant to multiple therapies including radiotherapy. In this study, we set up two GSLCs cell lines from the two parental U87 and U251 glioma cell lines, and studied the expression of apoptosis-related genes alteration in GSLCs before and after irradiation. We found that one of the receptors of TNF-related apoptosis-inducing ligand (TRAIL), DR5, was dramatically up-regulated in GSLCs after irradiation (IR). Although GSLCs are resistant to both TRAIL and radiation treatment alone, the combined treatment with TRAIL and irradiation achieved maximum killing effect of GSLCs due to inducing the expression of DR5 and inhibiting the expression of cFLIP. Therefore, TRAIL and IR combined treatment would be a simple but practical therapeutic strategy for clinical application.

show abstract

Section: Discussionmentioning

confidence: 99%

Synergistic effect of TRAIL and irradiation in elimination of glioblastoma stem-like cells

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Human CD133 (prominin-1), a 120-kDa cell-surface protein, has been accepted as the standard marker for the identi fication of GSCs, although it may not be exclusive or the most ideal marker for this cell type (30)(31)(32). ATP-binding cassette subfamily G (ABCG) is a membrane pump that consumes ATP to excrete endogenous small molecules, such as chole sterol, ions and peptides, across cell membranes.…”

Section: Discussionmentioning

confidence: 99%

β-elemene inhibits stemness, promotes differentiation and impairs chemoresistance to temozolomide in glioblastoma stem-like cells

Zhu

Luo

et al. 2014

International Journal of Oncology

View full text Add to dashboard Cite

Abstract. Accumulating evidence indicates that glioblastoma stem-like cells (GSCs) are key factors in tumour development, recurrence and chemoresistance. The impairment of stemness and the enhancement of differentiation contributes to the weakening of radiation and chemotherapy resistance of GSCs. We previously found that β-elemene was an effective anti-glioblastoma agent and chemosensitizer. In this study, we examined the distribution of CD133 + cells in human glioblastoma tissues by immunohistochemistry. Following treatment with β-elemene, the formation of GSC spheres was investigated by manual counting, the proliferation of GSCs was measured with a Cell Counting Kit-8 (CCK-8) assay, and the dispersion of GSC spheres was observed with an inverted microscope. GSC spheres were treated with β-elemene, and the expression levels of CD133, ATP-binding cassette subfamily G member 2 (ABCG2) and glial fibrillary acidic protein (GFAP) were examined by western blotting. After treatment with β-elemene, the volumes and weights of GSC xenografts were measured, and the expression of CD133, ABCG2 and GFAP was evaluated through immunohistochemistry analysis. After treatment with β-elemene and temozolomide (TMZ), GSC viability was examined by the CCK-8 assay, and the volumes and weights of xenografts were measured. We found that CD133 + cells were assembled in some vascular walls and also sparsely distributed in other parts of glioblastoma tissues. β-elemene decreased the formation of GSC spheres, dispersed GSC spheres and inhibited the proliferation of GSCs in vitro and in vivo. In the GSC spheres and xenografts treated with β-elemene, the expression of CD133 and ABCG2 was significantly downregulated, and the expression of GFAP increased. Furthermore, the sensitivity of GSCs to TMZ was enhanced in vitro and in vivo. These results suggest that β-elemene impaired the stemness of GSC spheres, promoted their differentiation and sensitized GSCs to TMZ. β-elemene will hopefully become a valuable agent to enhance the effects of radiotherapy and chemotherapy.

show abstract

“…Some researchers have found that GBM cells that express Prominin-1 (CD133) on their membrane show CSC-like properties. 41 These were called brain tumor stem cells (BTSCs), believed to be responsible for tumor growth, recurrence, and resistance to therapies. They share with NSCs antigenic properties of stemness, such as Nestin, Musashi-1, CD133, and SOX2 expression.…”

Section: Discussionmentioning

confidence: 99%

Distinctive effects of the cellular inhibitor of apoptosis protein c-IAP2 through stabilization by XIAP in glioblastoma multiforme cells

et al. 2014

View full text Add to dashboard Cite

CD133 as a Marker for Regulation and Potential for Targeted Therapies in Glioblastoma Multiforme

Cited by 31 publications

References 125 publications

Synergistic effect of TRAIL and irradiation in elimination of glioblastoma stem-like cells

Synergistic effect of TRAIL and irradiation in elimination of glioblastoma stem-like cells

β-elemene inhibits stemness, promotes differentiation and impairs chemoresistance to temozolomide in glioblastoma stem-like cells

Distinctive effects of the cellular inhibitor of apoptosis protein c-IAP2 through stabilization by XIAP in glioblastoma multiforme cells

Contact Info

Product

Resources

About